MedLink Global CMO Dr. Christoph Correll explains to Psychiatric Times why muscarinic treatment may be a presynaptic answer to the presynaptic problem at the core of schizophrenia.
MedLink Global CMO Dr. Christoph Correll joins Psychiatric Times to discuss reframing long-acting injectable antipsychotics as a path that supports, rather than limits, patient autonomy.
MedLink Global CMO Dr. Christoph Correll speaks with Psychiatric Times about how clinicians can uncover hidden medication nonadherence in patients with serious mental illness.
